Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease The COMPASS Trial
Rivaroxaban With or Without Aspirin in Patients With Heart Failure and Chronic Coronary or Peripheral Artery Disease The COMPASS Trial
复制标题
DOI：
10.1161/circulationaha.119.039609
复制
发表时间：
2019-08-13
期刊：
影响因子：
37.8
通讯作者：
Yusuf, Salim
中科院分区：
文献类型：
--
作者：
Branch, Kelley R.;Probstfield, Jeffrey L.;Yusuf, Salim
背景：患有慢性冠状动脉疾病或外周动脉疾病且有心力衰竭（HF）病史的患者发生主要不良心血管事件的风险较高。我们探讨了利伐沙班联合或不联合阿司匹林对这些患者的影响。方法：COMPASS 试验（使用抗凝策略的人群的心血管结果）将 27 395 名患有慢性冠状动脉疾病或外周动脉疾病的参与者随机分为利伐沙班 2.5 mg 每日两次加阿司匹林 100 mg 每日、单用利伐沙班 5 mg 每日两次或单用阿司匹林 100 mg。患有纽约心脏协会功能分级 III 或 IV HF 或左心室射血分数 (EF) 的患者
Background: Patients with chronic coronary artery disease or peripheral artery disease and history of heart failure (HF) are at high risk for major adverse cardiovascular events. We explored the effects of rivaroxaban with or without aspirin in these patients. Methods: The COMPASS trial (Cardiovascular Outcomes for People Using Anticoagulation Strategies) randomized 27 395 participants with chronic coronary artery disease or peripheral artery disease to rivaroxaban 2.5 mg twice daily plus aspirin 100 mg daily, rivaroxaban 5 mg twice daily alone, or aspirin 100 mg alone. Patients with New York Heart Association functional class III or IV HF or left ventricular ejection fraction (EF)